Protagonist Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: PTGX · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1377121
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Protagonist Therapeutics held a shareholder vote on June 20th. Details to follow.
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on matters submitted to a vote of security holders as of June 20, 2025. The filing does not contain specific details about the vote itself or any associated financial transactions.
Why It Matters
This filing indicates that Protagonist Therapeutics held a vote of its security holders, which could pertain to significant corporate actions or governance changes.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- June 20, 2025 (date) — Earliest event date
- June 26, 2025 (date) — Filing date
FAQ
What specific matters were submitted to a vote of Protagonist Therapeutics' security holders?
The filing does not specify the exact matters that were submitted to a vote of security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 20, 2025.
What is the principal business address of Protagonist Therapeutics, Inc.?
The principal executive address is 7707 Gateway Blvd., Suite 140, Newark, California 94560-1160.
What is the IRS Employer Identification Number for Protagonist Therapeutics, Inc.?
The IRS Employer Identification Number is 98-0505495.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Protagonist Therapeutics, Inc (PTGX).